Company Overview and News

1
Lithium Junior Miner News For The Month Of March 2018

2018-03-28 seekingalpha
Lithium spot and contract price news - Lithium spot prices moved sideways, whilst 2018 global LCE contract prices are up about 20%.
Upvote Downvote

 
Lithium Junior Miner News For The Month Of January 2017

2018-01-30 seekingalpha
Welcome to the January 2017 edition of the "junior" lithium miner news. I have categorized those lithium miners that won't likely be in production much before 2020 as the juniors, rather than market cap as that fluctuates too much.
Upvote Downvote

 
Make Your Own High-Risk/High-Reward Lithium ETF

2018-01-09 seekingalpha
These lithium stocks have the potential to provide a much better return on investment than the Global X Lithium & Battery Tech ETF.
Upvote Downvote

 
Lithium Junior Miner News For The Month Of December 2017

2017-12-28 seekingalpha
Lithium market news - Roskill has tripled their lithium demand forecast from last year, from 328ktpa to ~1mtpa by 2026.
Upvote Downvote

2
Lithium Junior Miner News For The Month Of November 2017

2017-11-29 seekingalpha
Lithium spot and contract price news: Spot prices were little changed over the month. SQM reports contract prices "surpassing US$13,000/ton."
Upvote Downvote

 
High Risk/High Reward Lithium Mining Companies To Invest In

2017-10-23 seekingalpha
This article would be a fitting prequel to my other recent article, located here: 4 Lithium Miner Stocks That Could Explode
Upvote Downvote

 
Cobalt Blue, AusQuest, Aus Tin Mining, Bass Metals, Dark Horse Resources, Lake Resources - Noosa Conference day-one

2017-07-19 proactiveinvestors.com.au
The first session of the Noosa Mining Exploration 2017 Conference carried us off on a world tour that took in Argentina, Peru and Madagascar - as well as Australia.
Upvote Downvote

 
Lake Resources NL samples elevated lithium results in Argentina

2017-02-06 proactiveinvestors.com.au
Lake Resources NL (ASX:LKE) has received elevated results of up to 322 mg/litre lithium from initial surface auger samples at the Kachi Lithium Brine Project in Catamarca, Argentina.
Upvote Downvote

 
Lake Resources NL's shares in pre-open pending capital raising details

2016-12-06 proactiveinvestors.com.au
The halt will remain in place until the opening of trade on Thursday 8th December 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
Lake Resources NL moves into the lithium triangle of Argentina

2016-11-29 proactiveinvestors.com.au
A number of leases have recently been granted to enable exploration, following the company’s acquisition of lithium brine lease applications in Argentina. The leases lie in the lithium triangle where the world’s largest and lowest cost production of lithium is located. Leases have been granted to allow exploration in the Kachi Project area (9,000 hectares) in the Catamarca Province, with a series of adjoining leases anticipated for similar granting soon.
Upvote Downvote

 
Lake Resources NL among ASX % Gainers intra-day

2016-05-25 proactiveinvestors.com.au
Lake Resources NL (ASX:LKE) is an Australian company that was formed in 1997 as a specialist mineral explorer with the objective of discovering world-class mineral deposits. The Company has exploration projects in Pakistan.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...